Merck & Co. is no longer in talks to purchase Revolution Medicines.

According to informed sources, Merck & Co. has stopped negotiating the acquisition of the biotechnology company Revolution Medicines. Merck has been in talks to acquire RevMed recently, with the potential deal valuing the cancer drug biotechnology company at around $30 billion. Some sources say that negotiations cooled off after the two parties failed to reach an agreement on price. Negotiations could potentially restart, or RevMed may attract another suitor. RevMed is expected to release highly anticipated test data for its pancreatic and colorectal cancer candidate drugs in the first half of this year.